Intercure (INCR) - Total Liabilities
Based on the latest financial reports, Intercure (INCR) has total liabilities worth ILA294.19 Million ILA (≈ $788.73K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Intercure (INCR) equity growth momentum to track the company's year-over-year net asset growth rate.
Intercure - Total Liabilities Trend (2008–2025)
This chart illustrates how Intercure's total liabilities have evolved over time, based on quarterly financial data. See Intercure (INCR) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Intercure Competitors by Total Liabilities
The table below lists competitors of Intercure ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Major Cineplex Lifestyle Leasehold Property Fund
BK:MJLF
|
Thailand | ฿175.96 Million |
|
Eonmetall Group Bhd
KLSE:7217
|
Malaysia | RM210.65 Million |
|
Sinsin Pharmaceutical Co. Ltd
KQ:002800
|
Korea | ₩65.10 Billion |
|
LORDS CHLORO ALKALI ORD T (BSE)
NSE:LORDSCHLO
|
India | Rs2.36 Billion |
|
Webstep ASA
OL:WSTEP
|
Norway | Nkr262.30 Million |
|
JAS Asset PCL
BK:J
|
Thailand | ฿3.18 Billion |
|
Fernheizwerk Neukölln Aktiengesellschaft
F:FHW
|
Germany | €46.74 Million |
|
Ananda Development Public Company Limited
BK:ANAN
|
Thailand | ฿17.27 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Intercure's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Intercure.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intercure's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intercure (2008–2025)
The table below shows the annual total liabilities of Intercure from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ILA294.19 Million ≈ $788.73K |
-19.38% |
| 2024-12-31 | ILA364.90 Million ≈ $978.29K |
+10.73% |
| 2023-12-31 | ILA329.55 Million ≈ $883.52K |
-24.51% |
| 2022-12-31 | ILA436.53 Million ≈ $1.17 Million |
+92.19% |
| 2021-12-31 | ILA227.13 Million ≈ $608.93K |
+564.88% |
| 2020-12-31 | ILA34.16 Million ≈ $91.58K |
+31.23% |
| 2019-12-31 | ILA26.03 Million ≈ $69.79K |
+60.12% |
| 2018-12-31 | ILA16.26 Million ≈ $43.59K |
+397.63% |
| 2017-12-31 | ILA3.27 Million ≈ $8.76K |
-10.88% |
| 2016-12-31 | ILA3.67 Million ≈ $9.83K |
+449.16% |
| 2015-12-31 | ILA667.52K ≈ $1.79K |
-65.65% |
| 2014-12-31 | ILA1.94 Million ≈ $5.21K |
-13.50% |
| 2013-12-31 | ILA2.25 Million ≈ $6.02K |
-52.13% |
| 2012-12-31 | ILA4.69 Million ≈ $12.58K |
-91.41% |
| 2011-12-31 | ILA54.64 Million ≈ $146.49K |
+309.28% |
| 2010-12-31 | ILA13.35 Million ≈ $35.79K |
+24.36% |
| 2009-12-31 | ILA10.73 Million ≈ $28.78K |
-71.12% |
| 2008-12-31 | ILA37.17 Million ≈ $99.65K |
-- |
About Intercure
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in… Read more